The persistence of aggressive breast cancer patterns in Black women demands urgent attention from both clinicians and patients navigating early detection strategies. Understanding these disparities could reshape screening protocols and treatment approaches for communities disproportionately affected by lethal tumor subtypes.
Analysis of 922 women from the Duke Breast Cancer MRI dataset revealed stark differences in cancer presentation patterns. Black women showed nearly 30% prevalence of triple-negative breast cancer, a particularly aggressive subtype lacking estrogen, progesterone, and HER2 receptors. Nearly half of Black patients presented with advanced stage III Nottingham grade tumors at diagnosis, compared to significantly lower rates in White patients. The median diagnosis age for Black women was younger, suggesting earlier onset disease.
These findings align with decades of cancer registry data showing persistent biological disparities, yet this study's controlled hospital cohort provides crucial insights. Triple-negative breast cancer responds poorly to hormone-blocking therapies that benefit other subtypes, requiring more intensive chemotherapy regimens. The concentration of aggressive tumor biology in Black women likely reflects complex interactions between genetic ancestry, environmental exposures, and healthcare access patterns. While overall mortality rates showed no significant differences after statistical adjustment, the small number of deaths limits definitive conclusions about survival disparities. This research reinforces the critical need for earlier, more frequent screening in Black women and highlights how tumor biology differences may require subtype-specific prevention strategies.